PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12942110-10	2003	The AUC(0-10 h) of uracil on day 5 was 252+/-60 ng h ml(-1) with PVI of 5-FU and 12 582+/-3060 ng h ml(-1) with S-1.	Uracil	19-25	proteasome 26S subunit, non-ATPase 1	Homo sapiens	112-115	
12942110-11	2003	The AUC(0-10 h) of FBAL was markedly lower and plasma uracil concentrations were significantly higher for S-1 than for PVI of 5-FU, clearly demonstrating the effect of DPD inhibition.	Uracil	54-60	proteasome 26S subunit, non-ATPase 1	Homo sapiens	106-109	
19921195-0	2010	Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?	Uracil	16-22	proteasome 26S subunit, non-ATPase 1	Homo sapiens	87-90	
21378348-11	2011	Following single- and multiple-dose administration of S-1, plasma concentrations of uracil returned to baseline levels within approximately 48 h of dosing, indicating reversibility of DPD inhibition by CDHP.	Uracil	84-90	proteasome 26S subunit, non-ATPase 1	Homo sapiens	54-57	
20500514-8	2010	These results suggest that the preferential anti-LNM activity of S-1 compared with UFT/LV against high-DPD COLM-5 tumors is due to the higher DPD inhibitory activity of 5-chloro-2, 4-dihydroxypyrimidine (CDHP) present in S-1 than uracil in UFT.	Uracil	230-236	proteasome 26S subunit, non-ATPase 1	Homo sapiens	65-68	
16897970-9	2006	The AUC0-10h of uracil on day 5 was 252 +/- 60 ng x hr/ml with PVI of 5-FU and 12,582 +/- 3,060 ng x hr/ml with S-1.	Uracil	16-22	proteasome 26S subunit, non-ATPase 1	Homo sapiens	112-115	
16897970-10	2006	The AUC0-10h of FBAL was markedly lower and plasma uracil concentrations were significantly higher for S-1 than for PVI of 5-FU, clearly demonstrating the effect of DPD inhibition.	Uracil	51-57	proteasome 26S subunit, non-ATPase 1	Homo sapiens	103-106